OK Biotech Co Ltd
TWSE:4155
OK Biotech Co Ltd
TWSE:4155
Price:
13.35
TWD
0.75%
Market Closed
Market Cap:
NT$1.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
SE |
|
A
|
AstraZeneca PLC
LSE:0A4J
|
UK |
|
FibroGen Inc
NASDAQ:FGEN
|
US |
OK Biotech Co Ltd
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
OK Biotech Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OK Biotech Co Ltd
TWSE:4155
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Medtecs International Corporation Ltd
SGX:546
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Visco Vision Inc
TWSE:6782
|
Research & Development
-NT$195.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
P
|
Pegavision Corp
TWSE:6491
|
Research & Development
-NT$622.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
SciVision Biotech Inc
TWSE:1786
|
Research & Development
-NT$93.2m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
No Stocks Found
OK Biotech Co Ltd
Glance View
OK Biotech Co. Ltd. engages in the manufacture, wholesale, trade, and retail of medical equipment and related homecare medical products. The company is headquartered in Hsinchu, Hsinchu. The company went IPO on 2010-12-30. The firm primarily provides household medical glucose meters and disposable glucose testing strips. Its products are applied in the testing and monitoring of glucose value for diabetes patients, hospitals, clinic doctors and nurses, among others. The firm distributes its products principally in Taiwan, other Asian markets and the United States.
Intrinsic Value
20.48
TWD
Undervaluation 35%
